Author:
Locke Frederick L,Ghobadi Armin,Jacobson Caron A,Miklos David B,Lekakis Lazaros J,Oluwole Olalekan O,Lin Yi,Braunschweig Ira,Hill Brian T,Timmerman John M,Deol Abhinav,Reagan Patrick M,Stiff Patrick,Flinn Ian W,Farooq Umar,Goy Andre,McSweeney Peter A,Munoz Javier,Siddiqi Tanya,Chavez Julio C,Herrera Alex F,Bartlett Nancy L,Wiezorek Jeffrey S,Navale Lynn,Xue Allen,Jiang Yizhou,Bot Adrian,Rossi John M,Kim Jenny J,Go William Y,Neelapu Sattva S
Reference29 articles.
1. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study;Crump;Blood,2017
2. Chimeric antigen receptor T-cell therapies for lymphoma;Brudno;Nat Rev Clin Oncol,2018
3. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma;Locke;Mol Ther,2017
4. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL;Abramson;J Clin Oncol,2018
5. Borchmann P, Tam CS, Jäger U, et al. An updated analysis of Juliet, a global pivotal phase 2 trial of tisagenlecleucel in adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). 23rd Congress of the European Hematology Association; Stockholm, Sweden; June 14–17, 2018; S799.
Cited by
1619 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献